Senti Biosciences, Inc. 已顺利完成其候选疗法Senti-202针对复发或难治性急性髓系白血病(R/R AML)的一期临床试验患者招募工作。这一关键进展标志着该疗法向临床开发的下一个阶段迈出了重要一步。
Senti Biosciences, Inc. 已顺利完成其候选疗法Senti-202针对复发或难治性急性髓系白血病(R/R AML)的一期临床试验患者招募工作。这一关键进展标志着该疗法向临床开发的下一个阶段迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.